282 related articles for article (PubMed ID: 15374990)
1. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models.
Busquets S; Fuster G; Ametller E; Olivan M; Figueras M; Costelli P; Carbó N; Argilés JM; López-Soriano FJ
Clin Nutr; 2007 Apr; 26(2):239-44. PubMed ID: 17261345
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats.
Carbó N; López-Soriano J; Costelli P; Busquets S; Alvarez B; Baccino FM; Quinn LS; López-Soriano FJ; Argilés JM
Br J Cancer; 2000 Aug; 83(4):526-31. PubMed ID: 10945502
[TBL] [Abstract][Full Text] [Related]
4. Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.
Kenley RA; Denissenko MF; Mullin RJ; Story J; Ekblom J
Oncol Rep; 2008 May; 19(5):1113-21. PubMed ID: 18425366
[TBL] [Abstract][Full Text] [Related]
5. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
6. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.
Fuster G; Busquets S; Ametller E; Olivan M; Almendro V; de Oliveira CC; Figueras M; López-Soriano FJ; Argilés JM
Cancer Res; 2007 Jul; 67(13):6512-9. PubMed ID: 17616713
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
Ryall JG; Sillence MN; Lynch GS
Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501
[TBL] [Abstract][Full Text] [Related]
8. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
9. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia?
van Royen M; Carbó N; Busquets S; Alvarez B; Quinn LS; López-Soriano FJ; Argilés JM
Biochem Biophys Res Commun; 2000 Apr; 270(2):533-7. PubMed ID: 10753659
[TBL] [Abstract][Full Text] [Related]
10. IGF-1 is downregulated in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bossola M; Penna F; Reffo P; Bonetto A; Busquets S; Bonelli G; Lopez-Soriano FJ; Doglietto GB; Argilés JM; Baccino FM; Rossi Fanelli F
Am J Physiol Regul Integr Comp Physiol; 2006 Sep; 291(3):R674-83. PubMed ID: 16614058
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis.
Tilignac T; Temparis S; Combaret L; Taillandier D; Pouch MN; Cervek M; Cardenas DM; Le Bricon T; Debiton E; Samuels SE; Madelmont JC; Attaix D
Cancer Res; 2002 May; 62(10):2771-7. PubMed ID: 12019153
[TBL] [Abstract][Full Text] [Related]
12. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia.
Costelli P; De Tullio R; Baccino FM; Melloni E
Br J Cancer; 2001 Apr; 84(7):946-50. PubMed ID: 11286475
[TBL] [Abstract][Full Text] [Related]
13. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.
Argilés JM; Figueras M; Ametller E; Fuster G; Olivan M; de Oliveira CC; López-Soriano FJ; Isfort RJ; Busquets S
Muscle Nerve; 2008 Feb; 37(2):190-5. PubMed ID: 17912749
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
Fontes-Oliveira CC; Busquets S; Toledo M; Penna F; Paz Aylwin M; Sirisi S; Silva AP; Orpí M; García A; Sette A; Inês Genovese M; Olivan M; López-Soriano FJ; Argilés JM
Biochim Biophys Acta; 2013 Mar; 1830(3):2770-8. PubMed ID: 23200745
[TBL] [Abstract][Full Text] [Related]
15. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.
Costelli P; García-Martínez C; Llovera M; Carbó N; López-Soriano FJ; Agell N; Tessitore L; Baccino FM; Argilés JM
J Clin Invest; 1995 May; 95(5):2367-72. PubMed ID: 7738199
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
17. Anticatabolic effect of the beta 2-agonist cimaterol in vivo in tumor-bearing animals.
Stallion A; Foley-Nelson T; Chance WT; James JH; Fischer JE
J Surg Res; 1995 Sep; 59(3):387-92. PubMed ID: 7643598
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Whitehouse AS; Smith HJ; Drake JL; Tisdale MJ
Cancer Res; 2001 May; 61(9):3604-9. PubMed ID: 11325828
[TBL] [Abstract][Full Text] [Related]
19. Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.
Quanjun Y; Genjin Y; Lili W; Bin L; Jin L; Qi Y; Yan L; Yonglong H; Cheng G; Junping Z
Mol Biosyst; 2013 Dec; 9(12):3015-25. PubMed ID: 24056883
[TBL] [Abstract][Full Text] [Related]
20. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.
Koopman R; Ryall JG; Church JE; Lynch GS
Curr Opin Clin Nutr Metab Care; 2009 Nov; 12(6):601-6. PubMed ID: 19741516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
